Top Banner
Perioperative use of Perioperative use of RAAS Antagonists: RAAS Antagonists: Evidence and Controversy Evidence and Controversy Moises Auron MD, FAAP Moises Auron MD, FAAP Department of Hospital Department of Hospital Medicine Medicine Cleveland Clinic Cleveland Clinic
46

Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Jun 12, 2015

Download

Documents

The clinician find a difficulty in deciding whether to continue or not the Renin-Angiotensin-Aldosterone Antagonists perioperatively. The evidence supporting and against its use is presented.
The clinician is advised about considering Aliskiren in the same context of RAAS antagonists.
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Perioperative use of RAAS Perioperative use of RAAS Antagonists: Evidence and Antagonists: Evidence and

ControversyControversy

Moises Auron MD, FAAPMoises Auron MD, FAAP

Department of Hospital MedicineDepartment of Hospital Medicine

Cleveland ClinicCleveland Clinic

Page 2: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Objectives

• Appraise the evidence supporting the current perioperative management of Renin-Angiotensin-Aldosterone system (RAAS) antagonists in non-cardiac surgery.

• Appraise the existence of newer RAAS antagonists such as Aliskiren (direct renin inhibitor) and its management in the perioperative setting.

Page 3: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Introduction

• The renin-angiotensin-aldosterone system (RAAS) antagonists (RAAS-antagonists) include: – Angiotensin-converting enzyme inhibitors

(ACEI) – Angiotensin II receptor subtype 1 blockers

(ARB)– Direct renin inhibitors (Aliskiren)– Aldosterone antagonists (Spironolactone,

Eplerenone)

Page 4: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

RAAS antagonists: indications

• Hypertension

• Congestive heart failure

• Coronary artery disease

• Diabetic nephropathy

• Prevention of progression of chronic renal failure

Ann Intern Med. 2008 Jan 1;148(1):16-29. J Card Fail. 2008 Apr;14(3):181-8. J Gen Intern Med. 2006 Dec;21(12):1242-7. Lancet. 2005 Dec 10;366(9502):2026-33. Curr Pharm Des. 2007;13(13):1335-45.

Page 5: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

RAAS antagonists and surgery

• Intra-operative hypotension after induction of anesthesia

• Post-operative acute renal failure

• Not associated with increased mortality

• All based on small studies

Anesth Analg. 1999 Nov;89(5):1143-55.Anesth Analg. 2001 Nov;93(5):1111-5.

Page 6: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

J Intern Med. 2008 Sep;264(3):224-36.

Page 7: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

J Intern Med. 2008 Sep;264(3):224-36.

Page 8: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Pharmacology of RAAS antagonists: perioperative implications

• Sympathetic blockade• Increase in the bioavailability of the vasodilatory agents:

– Bradykinin– Nitric oxide – Prostacyclines

• Inhibition of the vasoconstrictor effects of angiotensin II• Reduction in the secretion of aldosterone and ADH

– Decrease in renal salt and water reabsorption.

• Pleiotropic effects – inhibition of the different angiotensin peptides as well as both

renin and pro-renin receptors

Circulation. 2000 Jul 18;102(3):351-6.J Intern Med. 2008 Sep;264(3):224-36.

Page 9: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Effects of anesthesia on the BP

• Increased venous pooling of blood

• Decreased cardiac output

• Arterial hypotension.

Curr Pharm Des. 2003;9(9):763-76

Page 10: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Intra-operative BP

• Maintained by:– RAAS– Sympathetic nervous system – Arginine-vasopressine (AVP)

• Secretion stimulated as well by Angiotensin II

Curr Pharm Des. 2003;9(9):763-76

Page 11: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Intra-operative BP

• Multilevel effect for maintenance of intra-operative BP – Adequate hydration– Sympathomimetics– AVP agonists (terlipressin)

Page 12: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Pharmacogenomics of RAAS

• Genetic susceptibility to the RAAS-antagonists affected by single nucleotide polymorphism (SNP) mutations in:– Angiotensinogen– Angiotensin receptor 1– Angiotensin receptor 2.

• Affects intraoperative hemodynamic response to RAAS-antagonists.

Circulation. 2007 Feb 13;115(6):725-32. J Mol Med. 2008 Jun;86(6):637-41.

Page 13: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

ACEI

Am J Health Syst Pharm. 2004 May 1;61(9):899-912.

Page 14: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

ARB

Circulation 2001;103;904-912.

Page 15: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

EVIDENCE AGAINST

RAAS-ANTAGONISTS

Page 16: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Cleveland Clinic: IMPACT

• Current practice: discontinue both ACEI and ARB on the morning of surgery.

• Based on several small, controlled, randomized studies which found an increased frequency of refractory hypotension requiring intensive intravenous fluids and vasopressors after the induction of anesthesia when RAAS-antagonists were not discontinued preoperatively.

Cleve Clin J Med. 2006 Mar;73 Suppl 1:S82-7.

Page 17: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• Sublingual captopril (12.5 mg and 25 mg) vs. placebo 25 minutes before ETI

• N = 40

• Captopril - increased ↓BP (P <0.05) within 3 minutes after ETI– No significant difference between both doses.

Anaesthesia. 1990 Mar;45(3):243-5.

McCarthy

Page 18: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Coriat

• HTN patients on chronic ACEI - randomized 2 groups, - administration of ACEI in AM of surgery vs. withdrawn.

• Requirement of ephedrine:– Captopril (n = 36) 64% vs. 12% (P<0.05) – Enalapril (n = 20) 100% vs. 18% (P<0.005)

Anesthesiology. 1994 Aug;81(2):299-307.

Page 19: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Brabant• Hemodynamic response to induction between

ARB, beta-blockers (BB), Ca channel blockers (CB) and ACEI.

• ↓BP : SBP ↓ of > 30% from the preoperative value or an absolute SBP < 90 mm Hg. – ARB (12 of 12)– BB/CB-treated patients (27 of 45)– ACEI (18 of 27) (P< 0.05).

• ARB group – increased refractory to adrenergic agents (4 of 12) vs. BB/CB group (0 of 45) vs. ACEI (1 of 27).

• ↓BP - responsive to a vasopressin agonist.

Anesth Analg. 1999 Dec;89(6):1388-92.

Page 20: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Bertrand

• Patients on chronic therapy with ARB (N = 37)• 18 D/C ARB the day before sx vs. 19 received

ARB 1 h prior to induction.• ARB in AM of surgery - > frequent episodes and

longer duration of ↓BP.– ↓BP - refractory to adrenergic agents, requiring

terlipressin. – ARB dose < 10 hours of induction - > frequent

hypotensive episodes.

Anesth Analg. 2001 Jan;92(1):26-30.

Page 21: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Comfere

• Patients on chronic anti-HTN treatment with ACEI/ARB (N = 267)

• Incidence of ↓BP during the first 30 minutes after induction of anesthesia was more frequent in patients whose most recent ACEI/ARB was taken < 10 h. (60% vs. 46%, O.R. 1.74 (95% C.I. 1.03 to 2.93, P = 0.04)

Anesth Analg. 2005 Mar;100(3):636-44.

Page 22: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Shirmer

• Patients on chronic antiHTN with ACEI (N = 100) RCT.

• 50 received ACEI in AM of surgery vs. 50 who didn’t.

• BP and HR were significantly lower in the ACEI group requiring supportive adrenergic agonists – 17 of 50 in the ACEI vs. 5 of 50 in the

withdrawal group. Anaesthesist. 2007 Jun;56(6):557-61.

Page 23: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Licker

• Pts with CAD undergoing non-cardiac surgery • N = 32; 16 receiving chronic ACEI and 16 didn’t.• Induction-related ↓BP: 9 (ACEI) vs. 2 (control).

– Diminished response to phenylephrine in the ACEI group.

– Decreased -adrenergic vasoconstrictive response?

Can J Anaesth. 2000 May;47(5):433-40.

Page 24: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Kheterpal• Prospective observational study: N=

12,381 • Diuretics + ACEI/ARB increased ↓BP and

requirement for vasopressors vs. ACEI alone or when combination with Ca-vs.

• Propensity score matching and ROC curve analysis was done to control for comorbidities that may acquaint for hemodynamic variations between groups.

J Cardiothorac Vasc Anesth. 2008 Apr;22(2):180-6.

Page 25: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Rosenman

• Systematic review • Random-effects meta-analysis (incorporates

within-study and between-study variability)• 5 studies; N = 434 • Preoperative RAAS-antagonists on the day of

surgery – increased likelihood of ↓BP requiring vasopressors after induction (RR 1.50, 95% CI 1.15 to 1.96).

• No difference noted in incidence of peri-operative MI between groups (RR 0.41, 95% CI 0.07 to 2.53).

J Hosp Med. 2008 Jul;3(4):319-25.

Page 26: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Metaanalysis: Hypotension

J Hosp Med. 2008;3:319–325

Page 27: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Metaanalysis: AMI

J Hosp Med. 2008;3:319–325

Page 28: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

EVIDENCE SUPPORTING RAAS-ANTAGONISTS

Page 29: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• None of the studies showed any significant difference in postoperative complications.

• No proof of association between ↓BP and:– Major CV complications – Stroke– Renal failure– ICU LOS– Increased mortality

Page 30: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• Heropoulos– Assessment of hemodynamic and hormonal responses to:

• ETI• Incision• Limb-tourniquet inflation

– RCT; N = 30 patients undergoing limb surgery – Enalaprilat vs. placebo.

• - 1.25 mg IV 20 min prior to induction vs. 0.625 mg IV at the onset of tourniquet-associated hypertension.

– Venous blood samples for PRA and catecholamine (pre-intubation, 3 min post-intubation, 3 min post-incision, at onset of tourniquet hypertension, 3 min post-extubation and 1 hr postoperatively)

• No significant differences in catecholamine levels.

Anesth Analg. 1995 Mar;80(3):583-90.Drugs. 2007;67(7):1053-76.

Page 31: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• Pre-operative enalapril in balanced hypotensive anesthesia for cerebrovascular surgery.

• Controlled ↓BP - minimize intraoperative bleeding. RCT vs. placebo.

• Enalapril ↓ HTN response to ETI, ↓ postoperative vasodilators, more stable BP control.

• “Preoperative fasting may be the contributor to peri-operative ↓BP - improper fluid balance and Na2+ depletion - prevented by ensuring proper intravascular volume status”

J Neurosurg Anesthesiol. 1993 Jan;5(1):13-21.Acta Anaesthesiol Scand. 1996 Jan;40(1):132-3.

Tohmo and Karanko

Page 32: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

ACE and Atrial Fibrillation

• Non surgical patients - ACEI - 50% reduction in the risk of developing new-onset atrial fibrillation (AF)

• White– Preop ACEI or ARB and postop AF following cardiac

surgery (CABG or valvular surgery) – N = 338 patients (175 (51.8%) received preoperative

ACEI or ARB). – No association found between preop ACEI/ARB and

reduction in postop AF (adjusted OR 0.71, 95% CI 0.42 to 1.20).

– Larger number of patients is needed.

Eur J Cardiothorac Surg. 2007 May;31(5):817-20.

Page 33: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Boldt

• RCT (N = 88)• CABG • 4 groups of 22 patients each

– intravenous enalapril– enoximone (phosphodiesterase inhibitor)– clonidine – placebo (normal saline).

• Enalapril - following induction of anesthesia - lower levels of cardiac enzyme release– Cardioprotective effect of RAAS-antagonists against

ischemia/reperfusion injury

Heart. 1996 Sep;76(3):207-13.

Page 34: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Pigott

• N = 40 patients undergoing CABG • All patients were on chronic ACEI

– 20 continued – 20 suspended

• No significant difference between the groups in the frequency of hypotension during anesthesia.

• The group that withheld ACEI had postoperative hypertension that required vasodilators

Br J Anaesth. 1999 Nov;83(5):715-20.

Page 35: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

PERI-OPERATIVE RAAS-ANTAGONISTS AND RENAL FUNCTION

Page 36: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Colson

• RCT (N = 18)

• Short-term (2 days) pre-op captopril vs. placebo in CABG

• Captopril - better preserved RPF and GFR during CPB vs. placebo treated patients.

Anesthesiology. 1990 Jan;72(1):23-7.

Page 37: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Licker

– RCT (N = 20)– 11 – i.v. enalapril 50 mcg/kg; 9 – NS 0.9% at

induction of anesthesia for aortic surgery. – After infra-renal aortic cross

• Enalapril - ↑ DO2, ↑ splachnic perfusion, ↑GFR @ 24 h post-op. (43)

Br J Anaesth. 1996 May;76(5):632-9.

Page 38: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Benedetto• RCT (N= 536)

• Effect of pre-op ACEI on AKI (↓GFR > 50%) – CABG.

• Preop ACEI (N = 281) - ↓ post-op AKI (O.R. 0.48; 95% CI, 0.23 to 0.77; P < 0.04)

• Incidence of AKI requiring dialysis:– 2.4% in ACEI group vs. 6.3% in controls (P =

0.03). (44)

Ann Thorac Surg. 2008 Oct;86(4):1160-5.

Page 39: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Cittanova

• Prospective study (N = 249) - aortic surgery

• Chronic treatment with ACEI (withheld in AM) - only factor associated with significative postoperative renal impairment (O.R. 2.01 95% C.I. 1.05 to 3.83)

Anesth Analg. 2001 Nov;93(5):1111-5.

Page 40: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Kincaid

• Retrospective (N= 1209) – CABG

• Preop ACEI along with intra-op aprotinin – ARF (OR 2.9, 95% CI 1.4 to 5.8, P < 0.0001).

Ann Thorac Surg. 2005 Oct;80(4):1388-93

Page 41: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

RAAS-ANTAGONISTS IN NEURAXIAL ANESTHESIA

Page 42: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• Thoracic epidural anesthesia – resultant ↓BP from attenuation of efferent sympathetic drive– ↑ vasopressin concentrations – renin activity remains unchanged.

Eur J Anaesthesiol. 1992 Jan;9(1):63-9.Anesthesiology. 1994 May;80(5):992-9.

Page 43: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

• Hohne– Assessment of the initial (first 20 minutes)

hemodynamic effect of ACEI in spinal anesthesia for lower body procedures.

– RCT (21 on chronic ACEI vs. 21 control)– Decrease in BP was similar.– Plasma vasopressin and norepinephrine

levels increased.

Acta Anaesthesiol Scand. 2003 Aug;47(7):891-6.

Page 44: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Aliskiren

• Direct renin inhibitor

• Long half life (30 - 40h)

• Increased renal vasodilatory effect vs. ACEI and ARB. (59)

• Low oral bioavailability– Terminal half life is 24 hrs.

• Weak antihypertensive (second-line agent)

J Am Coll Cardiol. 2008 Feb 5;51(5):519-28.Circulation. 2008 Aug 12;118(7):773-84.Am J Health Syst Pharm. 2008 Jul 15;65(14):1323-32.

Page 45: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Conclusions

• RAAS-antagonists - associated with a variable incidence of hypotension during the initial 30 minutes after induction of anesthesia in non-cardiac surgery

• These hypotensive episodes have not been linked to any significant postoperative complications.

• The ACEI/ARB should be held at least 10 hours or for one dose before the induction of anesthesia.

Page 46: Perioperative Use of Renin-Angiotensin-Aldosterone System Antagonists

Conclusions (cont.)

• Careful hemodynamic monitoring

• Prevention of hypovolemia

• When to continue RAAS-antagonists?– Complicated hypertensive patient– Chronic heart failure of ischemic heart

disease– Cardiac surgery– Requires discussion with anesthesiologist